Search Results 51-60 of 2937 for Erleada
About this study. Study AG221-C-001 is a Phase 1/2, multicenter, open-label, dose-escalation, safety, PK/PD, and clinical activity evaluation of orally ...
Learn about the symptoms, causes and prevention of this cancer that starts in the rectum. Treatments include surgery, radiation therapy and chemotherapy.
ID-LV305 is a novel immunotherapy agent designed to target dendritic cells and stimulate the body's immune system to fight the spread and growth of cancer for ...
About this study. This pilot clinical trial studies the best dose of erlotinib hydrochloride and to see how well it works in preventing liver cancer in ...
The purpose of this study is to evaluate the safety and tolerability of multiple subcutaneous injections of a mutanome-directed active immunotherapy ...
The purpose of this study is to evaluate efficacy of atumelnant, compared with placebo, in reducing daily GC dosage while maintaining adrenal androgen control ...
The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill ...
Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.